PR

Procaps Group SANASDAQ PROC Stock Report

Last reporting period 30 Sep, 2023

Updated 20 Dec, 2024

Last price

Market cap $B

0.233

Micro

Exchange

XNAS - Nasdaq

PROC Stock Analysis

PR

Uncovered

Procaps Group SA is uncovered by Eyestock quantitative analysis.

Market cap $B

0.233

Dividend yield

Shares outstanding

112.82 B

Procaps Group SA is an international healthcare and pharmaceutical company. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

View Section: Eyestock Rating